Brief: Labcorp Launches Molecular Residual Disease And Liquid Biopsy Solutions
23/04/2025 12:06
April 23 (Reuters) - Labcorp Holdings Inc LH.N: LABCORP LAUNCHES MOLECULAR RESIDUAL DISEASE AND LIQUID BIOPSY SOLUTIONS LABCORP HOLDINGS - PLASMA DETECT NOW AVAILABLE FOR CLINICAL USE TO ASSESS RISK OF RECURRENCE IN STAGE III COLON CANCER PATIENTS Source text: ID:nPnXwmPma Further company coverage: LH.N ((reuters.briefs@thomsonreuters.com;))
Recent news on Labcorp Holdings
See all newsBrief: Labcorp And Epic Expand Collaboration To Advance Diagnostic Integration Across Hospitals And Health Systems
U.S. STOCKS ON THE MOVE-Quanta, O'Reilly Automotive, Avis
Labcorp lifts full‑year forecast as diagnostics business stays resilient (updated)
U.S. STOCKS ON THE MOVE-Qualcomm, Meta, Cardinal Health
U.S. STOCKS ON THE MOVE-Royal Caribbean, Labcorp, Textron